The company said total da Vinci procedures grew approximately 16% in Q1 2026 (approximately 17% in Q1 2025), it placed 431 da Vinci systems (367 in Q1 2025), and da Vinci 5 placements were 232 (147 in Q1 2025).

10-QQuarterly reportFiled Apr 22, 2026Period of report Mar 31, 2026Summary published (UTC) Oct 2, 2026

Key points

AI summary

The company said total da Vinci procedures grew approximately 16% in Q1 2026 (approximately 17% in Q1 2025), it placed 431 da Vinci systems (367 in Q1 2025), and da Vinci 5 placements were 232 (147 in Q1 2025).
The company said customers performed approximately 42,700 biopsy procedures with Ion systems in Q1 2026, compared with approximately 30,700 in Q1 2025. It said its Ion installed base was approximately 1,041 systems as of March 31, 2026, up 22% from approximately 853 systems a year earlier.
The company said operating lease revenue was $250 million for the 3 months ended March 31, 2026, compared with $195 million in 2025. Of this, variable lease revenue from usage-based operating lease arrangements was $157 million, compared with $112 million in 2025.
The company said it generated $0.91 billion of operating cash flow for the 3 months ended March 31, 2026, exceeding net income of $0.83 billion. It said it repurchased 2.3 million shares for $1.12 billion and used $528 million for business acquisitions.

Key figures

Quarter ended March 31, 2026

Revenue: $2.8B
Operating income: $855M
Net income: $822M
EPS: $2.28
Gross profit: $1.8B
Operating cash flow: $912M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

da Vinci Procedure Growth and System Placements

The company said total da Vinci procedures grew approximately 16% in Q1 2026 (approximately 17% in Q1 2025), it placed 431 da Vinci systems (367 in Q1 2025), and da Vinci 5 placements were 232 (147 in Q1 2025).

Source · Based on the MD&A text of the filing

Ion Biopsy Procedures and Installed Base

The company said customers performed approximately 42,700 biopsy procedures with Ion systems in Q1 2026, compared with approximately 30,700 in Q1 2025. It said its Ion installed base was approximately 1,041 systems as of March 31, 2026, up 22% from approximately 853 systems a year earlier.

Source · Based on the MD&A text of the filing

Operating Lease Revenue

The company said operating lease revenue was $250 million for the 3 months ended March 31, 2026, compared with $195 million in 2025. Of this, variable lease revenue from usage-based operating lease arrangements was $157 million, compared with $112 million in 2025.

Source · Based on the MD&A text of the filing

Operating Cash Flow and Key Uses of Cash

The company said it generated $0.91 billion of operating cash flow for the 3 months ended March 31, 2026, exceeding net income of $0.83 billion. It said it repurchased 2.3 million shares for $1.12 billion and used $528 million for business acquisitions.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.